Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
| Condition(s) | CADASIL |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years. |
| Who can participate | Inclusion Criteria for CADASIL Participants: 1. Must be at least 18 years old 2. Positive NOTCH3 genetic testing; OR a positive skin biopsy; OR a willingness to have a NOTCH3 genetic test completed prior to enrolling AND are at-risk for, or diagnosed clinically with, CADASIL 3. Willing to commit to three in-person visits (a baseline visit, an 18-month follow-up, and a 36-month follow-up) and to remote visits as needed by phone, email, mail or internet 4. Willing to provide documentation of all current medications to study team a. All medications will be allowed throughout the course of study. Documentation of medications will be used for analyses to assess potential impact of medications on study outcomes. 5. Willing and able to undergo an MRI scan and blood draw at each in-person visit 6. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Wisconsin, Madison |
| Locations | Los Angeles, California, United States; San Francisco, California, United States; Denver, Colorado, United States; Atlanta, Georgia, United States; Chicago, Illinois, United States; New York, New York, United States (+6 more sites) |
| Start date | 2022-06-03 |
| NCT ID | NCT05677880 |
| Official listing | https://clinicaltrials.gov/study/NCT05677880 |